APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Eosinophilic Esophagitis Drug

Eosinophilic esophagitis (EoE, also spelled eosinophilic oesophagitis), also known as allergic oesophagitis, is an allergic inflammatory condition of the esophagus that involves eosinophils, a type of white blood cell. Symptoms are swallowing difficulty, food impaction, vomiting, and heartburn.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Eosinophilic esophagitis (EoE, also spelled eosinophilic oesophagitis), also known as allergic oesophagitis, is an allergic inflammatory condition of the esophagus that involves eosinophils, a type of white blood cell. Symptoms are swallowing difficulty, food impaction, vomiting, and heartburn.

Eosinophilic esophagitis was first described in children but also occurs in adults. The condition is not well understood, but food allergy may play a significant role. The treatment may consist of removal of known or suspected triggers and medication to suppress the immune response.

This report studies the eosinophilic esophagitis drug market.

Selected research

Market Outlook & Growth Opportunities

Global Eosinophilic Esophagitis Drug Market Outlook and Growth Opportunities 2026

Report ID 173988720425 December 2025194 pages

Choose your research edition.

Industry ResearchEosinophilic Esophagitis Drug Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Eosinophilic Esophagitis Drug Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Eosinophilic Esophagitis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Eosinophilic Esophagitis Drug Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Eosinophilic Esophagitis Drug Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

Eosinophilic esophagitis (EoE, also spelled eosinophilic oesophagitis), also known as allergic oesophagitis, is an allergic inflammatory condition of the esophagus that involves eosinophils, a type of white blood cell. Symptoms are swallowing difficulty, food impaction, vomiting, and heartburn.

Eosinophilic esophagitis was first described in children but also occurs in adults. The condition is not well understood, but food allergy may play a significant role. The treatment may consist of removal of known or suspected triggers and medication to suppress the immune response.

This report studies the eosinophilic esophagitis drug market.

Read the full market overview

AstraZeneca, GSK and Bayer are the leading producers of eosinophilic esophagitis drug, which together account for about 80% of the market.

North America is the leading region, accounting for more than 30% of the market, followed by Europe at nearly 30%.

This report provides an overview of the global Eosinophilic Esophagitis Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Eosinophilic Esophagitis Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Eosinophilic Esophagitis Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Eosinophilic Esophagitis Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Eosinophilic Esophagitis Drug Segment by Company

AstraZeneca

GSK

Bayer

Adare Pharmaceuticals

DBV Technologies

Dr. Falk Pharma

Quorum Innovations

Takeda

Calypso

Celgene

Regeneron

Eosinophilic Esophagitis Drug Segment by Type

Budesonide

Fluticasone

Others

Eosinophilic Esophagitis Drug Segment by Application

Hospitals

Clinics

Drugstore

Eosinophilic Esophagitis Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Eosinophilic Esophagitis Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Eosinophilic Esophagitis Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Eosinophilic Esophagitis Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Eosinophilic Esophagitis Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Eosinophilic Esophagitis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Eosinophilic Esophagitis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Eosinophilic Esophagitis Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Eosinophilic Esophagitis Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Eosinophilic Esophagitis Drug industry.

Chapter 3: Detailed analysis of Eosinophilic Esophagitis Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Eosinophilic Esophagitis Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Eosinophilic Esophagitis Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Eosinophilic Esophagitis Drug Industry Trends Table 2. Eosinophilic Esophagitis Drug Industry Drivers Table 3. Eosinophilic Esophagitis Drug Industry Opportunities and Challenges Table 4. Eosinophilic Esophagitis Drug Industry Restraints Table 5. Global Eosinophilic Esophagitis Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Eosinophilic Esophagitis Drug Revenue Share by Company (2021-2026) Table 7. Global Eosinophilic Esophagitis Drug Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Eosinophilic Esophagitis Drug Sales Volume Share by Company (2021-2026) Table 9. Global Eosinophilic Esophagitis Drug Average Price (USD/Unit) of Company (2021-2026) Table 10. Global Eosinophilic Esophagitis Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Eosinophilic Esophagitis Drug Key Company Manufacturing Base & Headquarters Table 12. Global Eosinophilic Esophagitis Drug Company, Product Type & Application Table 13. Global Eosinophilic Esophagitis Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Eosinophilic Esophagitis Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Budesonide Table 18. Significant Companies of Fluticasone Table 19. Significant Companies of Others Table 20. Global Eosinophilic Esophagitis Drug Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Eosinophilic Esophagitis Drug Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Eosinophilic Esophagitis Drug Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Eosinophilic Esophagitis Drug Sales Volume Share by Type (2021-2026) Table 24. Global Eosinophilic Esophagitis Drug Sales Volume Share by Type (2027-2032) Table 25. Global Eosinophilic Esophagitis Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Eosinophilic Esophagitis Drug Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Eosinophilic Esophagitis Drug Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Eosinophilic Esophagitis Drug Sales Value Share by Type (2021-2026) Table 29. Global Eosinophilic Esophagitis Drug Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Hospitals Table 31. Significant Companies of Clinics Table 32. Significant Companies of Drugstore Table 33. Global Eosinophilic Esophagitis Drug Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Eosinophilic Esophagitis Drug Sales Volume by Application (2021-2026) & (K Units) Table 35. Global Eosinophilic Esophagitis Drug Sales Volume by Application (2027-2032) & (K Units) Table 36. Global Eosinophilic Esophagitis Drug Sales Volume Share by Application (2021-2026) Table 37. Global Eosinophilic Esophagitis Drug Sales Volume Share by Application (2027-2032) Table 38. Global Eosinophilic Esophagitis Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Eosinophilic Esophagitis Drug Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Eosinophilic Esophagitis Drug Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Eosinophilic Esophagitis Drug Sales Value Share by Application (2021-2026) Table 42. Global Eosinophilic Esophagitis Drug Sales Value Share by Application (2027-2032) Table 43. Global Eosinophilic Esophagitis Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Eosinophilic Esophagitis Drug Sales by Region (2021-2026) & (K Units) Table 45. Global Eosinophilic Esophagitis Drug Sales Market Share by Region (2021-2026) Table 46. Global Eosinophilic Esophagitis Drug Sales by Region (2027-2032) & (K Units) Table 47. Global Eosinophilic Esophagitis Drug Sales Market Share by Region (2027-2032) Table 48. Global Eosinophilic Esophagitis Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Eosinophilic Esophagitis Drug Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Eosinophilic Esophagitis Drug Sales Value Share by Region (2021-2026) Table 51. Global Eosinophilic Esophagitis Drug Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Eosinophilic Esophagitis Drug Sales Value Share by Region (2027-2032) Table 53. Global Eosinophilic Esophagitis Drug Market Average Price (USD/Unit) by Region (2021-2026) Table 54. Global Eosinophilic Esophagitis Drug Market Average Price (USD/Unit) by Region (2027-2032) Table 55. Global Eosinophilic Esophagitis Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global Eosinophilic Esophagitis Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Eosinophilic Esophagitis Drug Sales by Country (2021-2026) & (K Units) Table 58. Global Eosinophilic Esophagitis Drug Sales Market Share by Country (2021-2026) Table 59. Global Eosinophilic Esophagitis Drug Sales by Country (2027-2032) & (K Units) Table 60. Global Eosinophilic Esophagitis Drug Sales Market Share by Country (2027-2032) Table 61. Global Eosinophilic Esophagitis Drug Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Eosinophilic Esophagitis Drug Sales Value Market Share by Country (2021-2026) Table 63. Global Eosinophilic Esophagitis Drug Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Eosinophilic Esophagitis Drug Sales Value Market Share by Country (2027-2032) Table 65. AstraZeneca Company Information Table 66. AstraZeneca Business Overview Table 67. AstraZeneca Eosinophilic Esophagitis Drug Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 68. AstraZeneca Eosinophilic Esophagitis Drug Product Portfolio Table 69. AstraZeneca Recent Development Table 70. GSK Company Information Table 71. GSK Business Overview Table 72. GSK Eosinophilic Esophagitis Drug Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 73. GSK Eosinophilic Esophagitis Drug Product Portfolio Table 74. GSK Recent Development Table 75. Bayer Company Information Table 76. Bayer Business Overview Table 77. Bayer Eosinophilic Esophagitis Drug Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 78. Bayer Eosinophilic Esophagitis Drug Product Portfolio Table 79. Bayer Recent Development Table 80. Adare Pharmaceuticals Company Information Table 81. Adare Pharmaceuticals Business Overview Table 82. Adare Pharmaceuticals Eosinophilic Esophagitis Drug Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 83. Adare Pharmaceuticals Eosinophilic Esophagitis Drug Product Portfolio Table 84. Adare Pharmaceuticals Recent Development Table 85. DBV Technologies Company Information Table 86. DBV Technologies Business Overview Table 87. DBV Technologies Eosinophilic Esophagitis Drug Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 88. DBV Technologies Eosinophilic Esophagitis Drug Product Portfolio Table 89. DBV Technologies Recent Development Table 90. Dr. Falk Pharma Company Information Table 91. Dr. Falk Pharma Business Overview Table 92. Dr. Falk Pharma Eosinophilic Esophagitis Drug Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 93. Dr. Falk Pharma Eosinophilic Esophagitis Drug Product Portfolio Table 94. Dr. Falk Pharma Recent Development Table 95. Quorum Innovations Company Information Table 96. Quorum Innovations Business Overview Table 97. Quorum Innovations Eosinophilic Esophagitis Drug Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 98. Quorum Innovations Eosinophilic Esophagitis Drug Product Portfolio Table 99. Quorum Innovations Recent Development Table 100. Takeda Company Information Table 101. Takeda Business Overview Table 102. Takeda Eosinophilic Esophagitis Drug Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 103. Takeda Eosinophilic Esophagitis Drug Product Portfolio Table 104. Takeda Recent Development Table 105. Calypso Company Information Table 106. Calypso Business Overview Table 107. Calypso Eosinophilic Esophagitis Drug Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 108. Calypso Eosinophilic Esophagitis Drug Product Portfolio Table 109. Calypso Recent Development Table 110. Celgene Company Information Table 111. Celgene Business Overview Table 112. Celgene Eosinophilic Esophagitis Drug Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 113. Celgene Eosinophilic Esophagitis Drug Product Portfolio Table 114. Celgene Recent Development Table 115. Regeneron Company Information Table 116. Regeneron Business Overview Table 117. Regeneron Eosinophilic Esophagitis Drug Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 118. Regeneron Eosinophilic Esophagitis Drug Product Portfolio Table 119. Regeneron Recent Development Table 120. Key Raw Materials Table 121. Raw Materials Key Suppliers Table 122. Eosinophilic Esophagitis Drug Distributors List Table 123. Eosinophilic Esophagitis Drug Customers List Table 124. Research Programs/Design for This Report Table 125. Authors List of This Report Table 126. Secondary Sources Table 127. Primary Sources List of Figures Figure 1. Eosinophilic Esophagitis Drug Product Image Figure 2. Global Eosinophilic Esophagitis Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Eosinophilic Esophagitis Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Eosinophilic Esophagitis Drug Sales (2021-2032) & (K Units) Figure 5. Global Eosinophilic Esophagitis Drug Sales Average Price (USD/Unit) & (2021-2032) Figure 6. Global Eosinophilic Esophagitis Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Budesonide Image Figure 10. Fluticasone Image Figure 11. Others Image Figure 12. Global Eosinophilic Esophagitis Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Eosinophilic Esophagitis Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Eosinophilic Esophagitis Drug Sales Volume Share by Type (2021-2032) Figure 15. Global Eosinophilic Esophagitis Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Eosinophilic Esophagitis Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Eosinophilic Esophagitis Drug Sales Value Share by Type (2021-2032) Figure 18. Hospitals Image Figure 19. Clinics Image Figure 20. Drugstore Image Figure 21. Global Eosinophilic Esophagitis Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Eosinophilic Esophagitis Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Eosinophilic Esophagitis Drug Sales Volume Share by Application (2021-2032) Figure 24. Global Eosinophilic Esophagitis Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Eosinophilic Esophagitis Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Eosinophilic Esophagitis Drug Sales Value Share by Application (2021-2032) Figure 27. Global Eosinophilic Esophagitis Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global Eosinophilic Esophagitis Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Eosinophilic Esophagitis Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Eosinophilic Esophagitis Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Eosinophilic Esophagitis Drug Sales Value (2021-2032) & (US$ Million) Figure 32. North America Eosinophilic Esophagitis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Eosinophilic Esophagitis Drug Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Eosinophilic Esophagitis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Eosinophilic Esophagitis Drug Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Eosinophilic Esophagitis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Eosinophilic Esophagitis Drug Sales Value (2021-2032) & (US$ Million) Figure 38. South America Eosinophilic Esophagitis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Eosinophilic Esophagitis Drug Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Eosinophilic Esophagitis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Eosinophilic Esophagitis Drug Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Eosinophilic Esophagitis Drug Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Budesonide
  • Fluticasone
  • Others
Applications
  • Hospitals
  • Clinics
  • Drugstore
Companies covered
  • AstraZeneca
  • GSK
  • Bayer
  • Adare Pharmaceuticals
  • DBV Technologies
  • Dr. Falk Pharma
  • Quorum Innovations
  • Takeda
  • Calypso
  • Celgene
  • Regeneron

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Eosinophilic Esophagitis Drug Sales Value (2021-2032)
  4. 1.2.2 Global Eosinophilic Esophagitis Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Eosinophilic Esophagitis Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Eosinophilic Esophagitis Drug Market Dynamics
  1. 2.1 Eosinophilic Esophagitis Drug Industry Trends
  2. 2.2 Eosinophilic Esophagitis Drug Industry Drivers
  3. 2.3 Eosinophilic Esophagitis Drug Industry Opportunities and Challenges
  4. 2.4 Eosinophilic Esophagitis Drug Industry Restraints
3 Eosinophilic Esophagitis Drug Market by Company
  1. 3.1 Global Eosinophilic Esophagitis Drug Company Revenue Ranking in 2025
  2. 3.2 Global Eosinophilic Esophagitis Drug Revenue by Company (2021-2026)
  3. 3.3 Global Eosinophilic Esophagitis Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Eosinophilic Esophagitis Drug Average Price by Company (2021-2026)
  5. 3.5 Global Eosinophilic Esophagitis Drug Company Ranking (2024-2026)
  6. 3.6 Global Eosinophilic Esophagitis Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Eosinophilic Esophagitis Drug Company Product Type and Application
  8. 3.8 Global Eosinophilic Esophagitis Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Eosinophilic Esophagitis Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Eosinophilic Esophagitis Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Eosinophilic Esophagitis Drug Market by Type
  1. 4.1 Eosinophilic Esophagitis Drug Type Introduction
  2. 4.1.1 Budesonide
  3. 4.1.2 Fluticasone
  4. 4.1.3 Others
  5. 4.2 Global Eosinophilic Esophagitis Drug Sales Volume by Type
  6. 4.2.1 Global Eosinophilic Esophagitis Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Eosinophilic Esophagitis Drug Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Eosinophilic Esophagitis Drug Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Eosinophilic Esophagitis Drug Sales Value by Type
  10. 4.3.1 Global Eosinophilic Esophagitis Drug Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Eosinophilic Esophagitis Drug Sales Value by Type (2021-2032)
  12. 4.3.3 Global Eosinophilic Esophagitis Drug Sales Value Share by Type (2021-2032)
5 Eosinophilic Esophagitis Drug Market by Application
  1. 5.1 Eosinophilic Esophagitis Drug Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Drugstore
  5. 5.2 Global Eosinophilic Esophagitis Drug Sales Volume by Application
  6. 5.2.1 Global Eosinophilic Esophagitis Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Eosinophilic Esophagitis Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Eosinophilic Esophagitis Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Eosinophilic Esophagitis Drug Sales Value by Application
  10. 5.3.1 Global Eosinophilic Esophagitis Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Eosinophilic Esophagitis Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Eosinophilic Esophagitis Drug Sales Value Share by Application (2021-2032)
6 Eosinophilic Esophagitis Drug Regional Sales and Value Analysis
  1. 6.1 Global Eosinophilic Esophagitis Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Eosinophilic Esophagitis Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Eosinophilic Esophagitis Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Eosinophilic Esophagitis Drug Sales by Region (2027-2032)
  5. 6.3 Global Eosinophilic Esophagitis Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Eosinophilic Esophagitis Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Eosinophilic Esophagitis Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Eosinophilic Esophagitis Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Eosinophilic Esophagitis Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Eosinophilic Esophagitis Drug Sales Value (2021-2032)
  12. 6.6.2 North America Eosinophilic Esophagitis Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Eosinophilic Esophagitis Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Eosinophilic Esophagitis Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Eosinophilic Esophagitis Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Eosinophilic Esophagitis Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Eosinophilic Esophagitis Drug Sales Value (2021-2032)
  21. 6.9.2 South America Eosinophilic Esophagitis Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Eosinophilic Esophagitis Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Eosinophilic Esophagitis Drug Sales Value Share by Country, 2025 VS 2032
7 Eosinophilic Esophagitis Drug Country-level Sales and Value Analysis
  1. 7.1 Global Eosinophilic Esophagitis Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Eosinophilic Esophagitis Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Eosinophilic Esophagitis Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Eosinophilic Esophagitis Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Eosinophilic Esophagitis Drug Sales by Country (2027-2032)
  6. 7.4 Global Eosinophilic Esophagitis Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Eosinophilic Esophagitis Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Eosinophilic Esophagitis Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Eosinophilic Esophagitis Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Eosinophilic Esophagitis Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Eosinophilic Esophagitis Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 AstraZeneca
  2. 8.1.1 AstraZeneca Company Information
  3. 8.1.2 AstraZeneca Business Overview
  4. 8.1.3 AstraZeneca Eosinophilic Esophagitis Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 AstraZeneca Eosinophilic Esophagitis Drug Product Portfolio
  6. 8.1.5 AstraZeneca Recent Developments
  7. 8.2 GSK
  8. 8.2.1 GSK Company Information
  9. 8.2.2 GSK Business Overview
  10. 8.2.3 GSK Eosinophilic Esophagitis Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 GSK Eosinophilic Esophagitis Drug Product Portfolio
  12. 8.2.5 GSK Recent Developments
  13. 8.3 Bayer
  14. 8.3.1 Bayer Company Information
  15. 8.3.2 Bayer Business Overview
  16. 8.3.3 Bayer Eosinophilic Esophagitis Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Bayer Eosinophilic Esophagitis Drug Product Portfolio
  18. 8.3.5 Bayer Recent Developments
  19. 8.4 Adare Pharmaceuticals
  20. 8.4.1 Adare Pharmaceuticals Company Information
  21. 8.4.2 Adare Pharmaceuticals Business Overview
  22. 8.4.3 Adare Pharmaceuticals Eosinophilic Esophagitis Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Adare Pharmaceuticals Eosinophilic Esophagitis Drug Product Portfolio
  24. 8.4.5 Adare Pharmaceuticals Recent Developments
  25. 8.5 DBV Technologies
  26. 8.5.1 DBV Technologies Company Information
  27. 8.5.2 DBV Technologies Business Overview
  28. 8.5.3 DBV Technologies Eosinophilic Esophagitis Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 DBV Technologies Eosinophilic Esophagitis Drug Product Portfolio
  30. 8.5.5 DBV Technologies Recent Developments
  31. 8.6 Dr. Falk Pharma
  32. 8.6.1 Dr. Falk Pharma Company Information
  33. 8.6.2 Dr. Falk Pharma Business Overview
  34. 8.6.3 Dr. Falk Pharma Eosinophilic Esophagitis Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Dr. Falk Pharma Eosinophilic Esophagitis Drug Product Portfolio
  36. 8.6.5 Dr. Falk Pharma Recent Developments
  37. 8.7 Quorum Innovations
  38. 8.7.1 Quorum Innovations Company Information
  39. 8.7.2 Quorum Innovations Business Overview
  40. 8.7.3 Quorum Innovations Eosinophilic Esophagitis Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Quorum Innovations Eosinophilic Esophagitis Drug Product Portfolio
  42. 8.7.5 Quorum Innovations Recent Developments
  43. 8.8 Takeda
  44. 8.8.1 Takeda Company Information
  45. 8.8.2 Takeda Business Overview
  46. 8.8.3 Takeda Eosinophilic Esophagitis Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Takeda Eosinophilic Esophagitis Drug Product Portfolio
  48. 8.8.5 Takeda Recent Developments
  49. 8.9 Calypso
  50. 8.9.1 Calypso Company Information
  51. 8.9.2 Calypso Business Overview
  52. 8.9.3 Calypso Eosinophilic Esophagitis Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Calypso Eosinophilic Esophagitis Drug Product Portfolio
  54. 8.9.5 Calypso Recent Developments
  55. 8.10 Celgene
  56. 8.10.1 Celgene Company Information
  57. 8.10.2 Celgene Business Overview
  58. 8.10.3 Celgene Eosinophilic Esophagitis Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Celgene Eosinophilic Esophagitis Drug Product Portfolio
  60. 8.10.5 Celgene Recent Developments
  61. 8.11 Regeneron
  62. 8.11.1 Regeneron Company Information
  63. 8.11.2 Regeneron Business Overview
  64. 8.11.3 Regeneron Eosinophilic Esophagitis Drug Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Regeneron Eosinophilic Esophagitis Drug Product Portfolio
  66. 8.11.5 Regeneron Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Eosinophilic Esophagitis Drug Value Chain Analysis
  2. 9.1.1 Eosinophilic Esophagitis Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Eosinophilic Esophagitis Drug Sales Mode & Process
  6. 9.2 Eosinophilic Esophagitis Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Eosinophilic Esophagitis Drug Distributors
  9. 9.2.3 Eosinophilic Esophagitis Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst